The neuropathological hallmark of the C9orf72 intronic hexanucleotide expansion in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) is the presence of small ubiquitin/p62-positive and transactive response DNA binding protein 43 kDa (TDP-43)-negative cytoplasmic inclusions in several brain areas. The identification of this histopathological signature is highly predictive of an underlying mutation. In this study, we screened 1800 cases of the Barcelona IDIBAPS Brain Bank, independently of the clinical and final neuropathological diagnosis of the brain donor, for the presence of ubiquitin/p62-positive inclusions in the cerebellum (UPPI). Positive cases were also stained for dipeptide repeats. We identified a total of 21 donors with UPPI and in all of them the C9orf72 hexanucleotide expansion was genetically confirmed. Most donors had an FTLD or to a lesser extent ALS clinico-pathological phenotype. However, 3 cases had been previously classified as having clinically and neuropathologically Lewy body disease. Other co-existing pathologies, especially of the PARTtype, were also frequently encountered. This study highlights the importance of the evaluation of ubiquitin/p62-positive cytoplasmic inclusions in all neurodegenerative diseases as a good screening method for the detection of C9orf72 expansion mutation, since this mutation is not rare and can overlap with other neurodegenerative entities.
INTRODUCTION
The neuropathological assessment of postmortem brain still represents the gold standard for the definite diagnosis of most sporadic neurodegenerative diseases. Their pathomorphological substrate and their classification are based on the identification of abnormally accumulated intra-or extracellular protein aggregates. Frontotemporal lobar degeneration (FTLD) encompasses a clinically and pathologically heterogeneous group of diseases. Clinically, patients may manifest with behavioral or language impairment and/or degeneration of motor neurons. From a neuropathological point of view, different substrates have been described: accumulation of hyperphosphorylated tau, those accumulating transactive response DNA binding protein 43 kDa (TDP-43) or proteins of the FET family (i.e. FUS, Ewing sarcoma, TAF15) (1, 2) . TDP-43 protein deposition has been recognized as a major component in a subgroup of FTLD as well as in motor neuron diseases (MND) such as amyotrophic lateral sclerosis (ALS). Thus, TDP-43 proteinopathies link molecularly and neuropathologically 2 phenotypic ends of a disease spectrum: frontotemporal dementia and ALS (3) .
A hexanucleotide expansion within the first intron of the chromosome 9 open reading frame 72 gene (C9orf72) has been observed in 20%-40% of FTLD and ALS, more frequently in cases with a family history (4) . Currently, it seems to be the most frequent mutation associated with these diseases, which has awakened great interest among the scientific community. Pathogenically, the expansion can silence transcription or alter it in such a way that RNA fragments containing the nucleotide expansion accumulate in the nucleus and sequester normal RNA and other proteins implicated in the regulation of transcription (5, 6) . Morphologically, there is an accumulation of dipeptide repeat (DPR) produced via repeat-associated non-ATG translation in neurons of the central nervous system. These can be identified by immunohistochemistry and their presence is highly predictive of carrying the expansion, being a quite unique situation in the field of neurodegeneration (7) (8) (9) . Besides abnormal neuronal TDP-43 protein aggregates, C9orf72 cases have small, star-like ubiquitin, p62 and DPR-positive/TDP-43-negative aggregates in granule cells of the dentate gyrus and pyramidal neurons of hippocampus, granule cells of cerebellar cortex and in neocortical neurons.
The aim of this study was to assess the prevalence of ubiquitin/p62-positive inclusions (UPPI) in a large postmortem series of the Neurological Tissue Bank (NTB) of the Biobanc-Hospital Clinic-Institut d'Investigacions Biomèdi-ques August Pi i Sunyer (IDIBAPS) and to determine its predictive value for the detection of an underling C9orf72 hexanucleotide expansion.
MATERIALS AND METHODS
The study has been performed on 2 cohorts: 1) a retrospective cohort comprising 1500 samples of formalin-fixed and paraffin embedded cerebellar cortex from the archives of the NTB, and 2) a prospective cohort of newly collected brains during the last 3 years period (300 new brains collected). The NTB was created 25 year ago, in the early 1990's, and has focused on the collection of brain and spinal cord of patients mainly affected by neurodegenerative conditions (www.clinicbiobanc.org). It is based on a brain donor program that covers the region of Catalonia (about 7.5 million inhabitants), where potential donors or their legal representative give their written consent for the use of the brain tissue for diagnostic and research purposes. Brain Donors are especially recruited from memory and movement disorders units from the major university hospitals, but also from geriatric clinics. Among the 1800 cases (99% European descendent), approximately 40% correspond to Alzheimer pathology, 10% to prion diseases, 10% to Lewy body disorders (LBD), (i.e. Parkinson disease and dementia with Lewy bodies [DLB]), 4% to progressive supranuclear palsy, 4% to FTLD-TDP, 4% to ALS, 2.5% to multiple system atrophy, 2% to corticobasal degeneration, 2% to genetic counterparts (e.g. PSEN, APP, MAPT, PGRN, TARDBP, LRRK2 and Parkin mutations), 2% to inflammatory conditions (e.g. demyelinating, autoimmune), 1.5% to trinucleotide repeat disorders (e.g. Huntington, SCA, FXTAS), 2% to cerebrovascular pathology, 12.5% to "other", and 2.5% to controls.
UPPI screening was evaluated by immunohistochemistry applying antibodies against ubiquitin (Dako, Glostrup, Denmark, polyclonal rabbit, dilution 1/400) and p62 (BD Biosciences, San Jose, CA, purified mouse antip62 LCK ligand, dilution 1/500). In addition, in positive cases, anti-TDP-43 (Abnova, Taipei, Taiwan, clone 2E2-D3, dilution 1/500), anti-DPR (C9RANT, Novus Biologicals Bionova, Littleton, CO, rabbit polyclonal, dilution 1/2000), anti-Tau (Thermo Scientific, Rockford, IL, clone AT8, dilution 1/2000), anti-b-amyloid (Dako, clone 6 F/3 D, dilution 1/400) and anti-a-synuclein (Novocastra, Newcastle, UK, clone KM51, dilution 1/200) antibodies were applied on an automated immunostainer (Dako autostainer plus) on 5-lm-thick sections cut from formalin-fixed, paraffinembedded tissue blocks. In doubtful or in positive cases, hippocampus and frontal cortex were also assessed.
Informed consent was obtained from brain donors and/ or relatives for the use of brain tissue for diagnostic and research purposes at the Brain Bank. The project was approved by our local Ethics Committee of the Hospital Clinic (HCB/ 2014/0301). Classification of main pathology and concomitant pathologies was made according to international accepted diagnostic criteria (10) . The genetic analysis of the C9orf72 hexanucleotide expansion in cases with UPPI was performed in collaboration with the Alzheimer and other cognitive disorders Unit from the Hospital Clinic-IDIBAPS and Hospital de Sant Pau, Barcelona, and the University of Antwerp, Belgium, within a collaborative pan-European study (11) . In that study, 22 FTLD and 17 ALS cases from our Brain Bank were screened for the mutation. DNA was obtained from deep frozen tissue at À80 C using a commercially available kit: QIAamp DNA kit (QIAGEN, Hilden, Germany). The C9orf72 repeat was typed by repeat-primed PCR and fragment-length analysis, as described (12) . Analysis of the C9orf72 risk haplotype was not performed. Clinical data was provided by the treating clinicians from different centers in Catalonia, Spain. In the cases in which the expansion was found, we offered genetic counselling for relatives within the Genetic counselling program for familial dementias (PICOGEN) program (13) from our center.
RESULTS
We identified UPPI in 21 adult brain donors among 1800 cases studied with different neurodegenerative diseases. All of them carried the C9orf72 expansion mutation (Table) . Six patients had been identified previously within a panEuropean collaborative genetic study (11) , 5 patients were diagnosed during life by their treating neurologist, and 10 patients have been identified at the Brain Bank due to characteristic neuropathological findings (3 cases retrospectively and 7 cases prospectively).
Clinical Data
The group consists of 11 female and 10 male patients with clinical onset ranging from 35 years (case 21) to 85 years (case 13) (mean 68 years). Disease duration ranged from 1 to 26 years (mean 6 years). Most patients (13/21; 62%) had behavioral alterations and were clinically diagnosed as a behavioral variant of FTD (bvFTD) (14, 15) (Table) . Motor-neuron signs were clinically evident in 8 patients (38%). The first diagnosis was FTLD in 5 of them and ALS in 3. Two patients had received the clinical diagnosis of Alzheimer disease (AD) and 4 of DLB (see below). 
Frequent bvFTD, frontotemporal degeneration behavioral variant; ALS, amyotrophic lateral sclerosis; DLB, dementia with Lewy bodies; LDB, Lewy body disease; CBD, corticobasal degeneration; PPA, primary progressive aphasia; PD, Parkinson disease; MSA, multiple system atrophy; AD, Alzheimer disease; FTLD, frontotemporal lobar degeneration; NCI, neuronal cytoplasmic inclusions; DN, dystrophic neurites; ADNC, Alzheimer disease neuropathologic change; MND, motor neuron disease; PART, primary age-related tauopathy; CAA, cerebral amyloid angiopathy; HS, hippocampal sclerosis; AgD, argyrophilic grain disease; LB, Lewy body.
Neuropathological Findings
All C9orf72 mutation carriers exhibited TDP-43 pathology. These 21 cases showed the typical UPPI in granule cells of the cerebellar cortex, hippocampus (dentate gyrus and pyramidal neurons of CA4-CA1), and neocortex at neuropathological examination. In 5 cases, the cerebellum showed isolated or clustered inclusions that were much better seen in frontal cortex and hippocampus (Table; Fig. 1 ). Inclusions were well identified using either anti-ubiquitin, p62 or DPR immunostaining, although ubiquitin showed a more widespread and higher density of pathology ( Fig. 1) , probably reflecting its lower specificity and broad ubiquitination of molecules.
Eighty-six percent of cases showed characteristic FTLD-TDP pattern (18/21), mainly type B (16/18, 89%) with abundant "preinclusion" type or diffuse cytoplasmic neuronal TDP-43 protein accumulations, especially when associated with MND. In 2 cases, FTLD pattern could not be assessed due to the paucity of TDP-43 protein aggregates (cases 5 and 11). Motor neuron involvement was present in 12/21 cases; in 10 patients this was observed in addition to the FTLD pattern. Of these, a preferential loss of motor neurons of the anterior horn of the spinal cord with preservation of upper motor neurons and of the corticospinal tract was present in 2 patients (20%), while the other 8 had an ALS pattern (80%). No one had upper motor neuron involvement only. Two cases had relatively pure ALS-TDP.
Concomitant pathologies were detected in 19/21 cases (90%) ( Table) and included primary age-related tauopathy (PART) (13/19, 68%): definite in 10 (77%) and probable in 3 (23%) cases. Low to intermediate AD neuropathologic change was observed in 4 patients (21%), argyrophilic grain pathology in 2 (11%) (i.e. 1 ALS and 1 FTLD), while a-synuclein-positive Lewy body pathology was detected in 3 cases (up to limbic stages) (16%). Two of these cases fulfilled clinical criteria of DLB and had been classified as LBD in the past.
Unexpected Mutation Carriers
Five out of 21 patients were not diagnosed with clinical syndromes within the FTD-ALS continuum during life. The appearance of gait problems, visual hallucinations and/or hypersensitivity to neuroleptic drugs in addition to the late-onset (>65 years) of cognitive impairment suggested a diagnosis of DLB in 4 of them.
Case 8 was a 73-year-old man presenting with progressive cognitive impairment, followed by gait problems and visual hallucinations. MRI neuroimaging showed diffuse asymmetric cortico-subcortical atrophy. The clinical diagnosis was probable DLB. Neuropathology showed neuronal loss, gliosis and a-synuclein-immunoreactive Lewy body pathology in intermediolateral column of the spinal cord, several brainstem nuclei including the dorsal motor nucleus of the vagal nerve, formatio reticularis, locus coeruleus, raphe, substantia nigra, as well as in the olfactory bulb, amygdala, transentorhinal region, nucleus basalis Meynert, and cingulum, overall consistent with a limbic predominant Lewy body disease. AT8-positive neurofibrillary pathology was mainly observed in termporo-medial regions including ento-and transentorhinal cortex, hippocampus CA1 sector, amygdala and temporo-occipital cortex, without betaA4-amyloid pathology, corresponding to primary age-related tauopathy (PART definite or Braak neurofibrillary stage III). In addition, superficial laminar spongiosis was observed in frontal and temporal Table) with different amounts of cerebellar and hippocampal inclusions: (A1) anti-ubiquitin immunohistochemistry reveals abundant small spherical cytoplasmic inclusions in granule cells of the cerebellum. In contrast, in the dentate gyrus of the hippocampus (A2), much less small spherical inclusions are detected. There are also some larger fibrillar and ring-like inclusions, that correspond to TDP-43 protein aggregates (A4). (A3, A5) Antidipeptide-repeat immunohistochemistry (C9RANT) confirms that ubiquitinated inclusions in cerebellar and dentate gyrus granule cells (arrows) correspond to the C9orf72 product. (B1) Only few ubiquitinpositive inclusions are detected in cerebellar granule cells, that are also labelled by C9RANT (B3, arrows). There are much more abundant inclusions in dentate gyrus of the hippocampus (B2), but they are larger and mostly correspond to TDP-43 protein aggregates (B4), rather than to dipeptide-repeats (B5, arrows), which are found in moderate amount.
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areas devoid of Lewy body pathology. Here neuronal cytoplasmic and isolated intranuclear TDP-43 protein inclusions were observed in superficial and middle cortical layers, striatum and in granular neurons of the dentate gyrus. These changes were also consistent with an FTLD-TDP type B pattern. Case 13 was an 85-year-old woman who suffered from progressive multidomain cognitive impairment and occasional visual hallucinations. MRI showed moderate chronic microangiopathy. The clinical diagnosis was mixed dementia. Postmortem brain gross examination revealed a severe atrophy accentuated in fronto-temporal regions. Histology showed diffuse neuronal loss and gliosis throughout fronto-temporoparietal regions accentuated in superficial cortical layers with laminar spongiosis. There was also diffuse gliosis of basal ganglia, segmental hippocampal sclerosis, and mild loss of pigmented neurons of substantia nigra. Immunohistochemistry revealed abundant neuronal TDP-43 protein inclusions in superficial and middle cortical layers, along with thin and thicker neurites inclusions in affected cortical areas, granule cells of hippocampus, amygdala, cingulate, striatum, and brainstem nuclei and few oligodendroglial inclusions were detected in white matter tracts. The neuropathological diagnosis was consistent with FTLD-TDP type B.
Case 15 was a 72-year-old man presenting with rapidly progressive cognitive impairment, mild parkinsonism and hypersensitivity to neuroleptics. The clinical diagnosis was DLB vs AD. Neuropathological examination revealed an FTLD pattern with cortical and subcortical involvement including striatum, thalamus, limbic system and substantia nigra. Superficial laminar spongiosis was most prominent in the cingulate, and relatively prominent gliosis was observed in the caudate and the thalamus. TDP-43 protein inclusions were detected in small neurons of superficial cortical layers and in isolated granule cells of the dentate gyrus but were more frequent in basal ganglia. They were also observed in periaqueductal grey matter and substantia nigra. Oligodendroglial inclusions were detected in pencil fibers and internal capsule. Moderate concomitant AT8-positive neurofibrillary pathology was seen in hippocampus and parahippocampal region, with no b-A4-plaque pathology.
Patient 16 showed cognitive impairment with hallucinations, gait apraxia and a focal motor deficit in the left lower limb beginning at the age of 67. Electromyography (EMG) was reported to be normal at first examination and no repeated EMGs were performed. MRI showed subcortical atrophy with moderate-severe ventricular enlargement. Normotensive hydrocephalus was suspected and ruled out. The final clinical diagnosis was DLB, although corticobasal degeneration was also considered due to the asymmetric motor deficit. Postmortem brain examination revealed a moderate prefrontal, hippocampal and amygdala atrophy, a moderate enlargement of the lateral ventricles and diffuse thinning of anterior roots of the spinal cord. Brainstem nuclei were regularly pigmented. Histology showed a mild FTLD pattern with preferential involvement of temporo-medial regions, thalamus and a more prominent involvement of both, upper and lower motor neurons, with degeneration of the corticospinal tract. Compact and skein-like TDP-43 protein inclusions were mainly observed in motor neurons of the hypoglossal nucleus and of the anterior horns. Only scarce TDP-43 aggregates were detected in septal nuclei, granule cells of the dentate gyrus, and cortical neurons. Concomitant AD neuropathologic changes consisting of AT8-positive neurofibrillary tangles and neuropil threads were observed in temporomedial regions along with moderate neuritic plaques and more extensive b-A4 amyloid deposits involving cortical and limbic regions, basal ganglia, brainstem and cerebellum. The patient had also small vessel pathology with multiple microinfarcts in cortical areas, basal ganglia and in the cerebellum. No Lewy bodies or astrocytic plaques were observed.
Patient 19 showed progressive cognitive impairment, atypical parkinsonism, visual hallucinations and neuroleptic hypersensitivity starting at the age of 75 followed by progressive dysphagia. EMG was not performed. The clinical diagnosis was probable DLB. Gross brain examination showed severe bilateral nigral pallor, without obvious brain atrophy. Histology revealed classical brainstem and limbic a-synuclein-immunoreactive Lewy body pathology involving vulnerable neuronal populations, corresponding to limbic predominant LBD. In addition, superficial cortical spongiosis was observed in frontal, and to a lesser extent in temporal cortex in areas devoid of LB but with mild TDP-43 and more abundant p62/C9RANT pathology. Mild AT8-positive neurofibrillary pathology and few diffuse b-A4 deposits, without neuritic plaques, and moderate small vessel pathology with microinfarcts in basal ganglia were also detected.
DISCUSSION
The neuropathology of the abnormal hexanucleotide expansion in C9orf72 offers a unique opportunity to perform a genetic diagnosis based on histological findings. Here, we show our experience at the Hospital Clinic-IDIBAPS Brain Bank where we found 21 cases with this genetic abnormality among 1800 brains. While 6 cases were identified in a panEuropean genetic study analyzing FTD and ALS cases (11), 5 were already diagnosed during life. This mutation represents 15% of our unselected FTLD and ALS Brain Bank cases (n ¼ 140). This frequency is comparable to those in other European countries as observed in the pan-European study, which ranged from 4.8% to 29.33% (11); the frequency in Spain (from a total of 50 subjects, including brain donors and living patients), was 25.49%. Interestingly, 10 C9ORF72 mutation carriers were only identified by the recognition of ubiquitin positive inclusions in granule cells of cerebellum and in the dentate gyrus of hippocampus, and 3 of them after a retrospective immunohistochemical review of archival cases. These findings indicate the importance of neuropathological studies as they might help to identify cases not suspected during life.
Our cases follow the same pattern of aggregation and distribution as those described so far (7, 8) . DPR pathology forms star-like cytoplasmic inclusions affecting neurons of hippocampus (dentate granule cells and CA3/4 portion of the pyramidal layer), molecular layer of cerebellum and neocortex. The cerebellum is a very useful site to search for this pathology because the granular layer is usually devoid of ubiquitin-positive pathology in many neurodegenerative conditions. Cerebellum is also considered 1 of the sites with higher prevalence of DPR inclusions (16) . However, in our series, a small fraction of cases disclosed more abundant DPR inclusions in neocortical regions and hippocampus, rather than in the cerebellum. This reinforces the importance of searching these inclusions in several brain areas to avoid dismissing this hallmark by only looking at a single region. This might be especially important in cases with short disease duration or bearing short expansions. Gami et al have identified 3 "incidental" mutation cases (expansion length of 20-40-unit G 4 C 2 ) in a brain bank screening of 86 cognitively normal older subjects without TDP-43 pathology. One case showed no p62/DPR pathology whereas in the other 2 cases it was only mild (17) . The authors suggest that a critical unit repeat length might be required to initiate accumulation of DPR.
While this study did not aim to perform a detailed mapping of pathology, many studies do not find a solid relationship between DPR pathology and neurodegeneration (18, 19) , and it is still unknown why DPR aggregates follow this deposition pattern. It is commonly accepted that TDP-43 pathology, which is related to C9orf72 does cause neurodegeneration (20, 21) . However, the relationship between DPR and TDP-43 is still unknown, and although both pathologies may involve topographically related areas, they are usually not present in the same neuron (22) . Baborie et al identified 3 mutation carriers (expansion length from 450 to >3600) among 22 FTLD patients, who died prematurely within 3 years of disease onset. They found abundant DPR inclusions but only sparse or even absent TDP-43 aggregates and only mild signs of neurodegeneration, suggesting that DPR formation precedes the accumulation of TDP-43 (23) . While we did not analyze the expansion length, we have also observed a discrepancy between the extent of p62/DPR and TDP-43 pathology in some of our cases, which was not related to disease duration.
In addition to the characteristic neuropathological findings, our cases showed other concomitant pathologies. Primary age related tauopathy (PART) was a frequent finding. Only 2 patients had intermediate or high AD neuropathological changes (24) , and 2 patients had argyrophilic grain pathology. Although to a lesser extent, these findings are in line with those of Bieniek et al, who analyzed the frequency of AD neuropathologic changes in a series of 17 FTLD-TDP cases with C9orf72 mutation. The authors found 4 cases with intermediate to high likelihood of AD (25) . This frequency was higher than in FTLD cases associated with progranulin mutations but not than in sporadic FTLD counterparts. Concerning neurofibrillary pathology, the median Braak stage was II-III and 5/17 cases had NFT stage IV or higher. They observed that FTLDC9orf72 cases had overall higher neurofibrillary pathology compared to FTLD-GRN or sporadic FTLD (25) . These differences were not related to other risk factors for AD pathology such as age, gender or ApoE e3 carrier state.
From the retrospective archival series, we also found 3 brain donors with Lewy body pathology in a limbic stage. These patients had a clinical diagnosis of cognitive impairment with visual hallucinations and were therefore finally diagnosed as Lewy body dementia. The observation of neuronal loss and superficial cortical spongiosis in areas devoid of LB and the identification of typical DPR aggregates together with TDP-43 and the presence of Lewy bodies in a typical brainstem and limbic distribution, led to rediagnose these cases as a FTLD and coexisting Lewy body pathology. It is, however, difficult to retrospectively interpret to which extent Lewybody and FTLD pathology contributed to clinical symptoms. Concomitant pathologies might modulate the clinical phenotype, especially psychiatric symptoms and cognition and may masquerade the coexistence of a C9orf72 expansion. This reinforces the importance of the screening of the cerebellum and hippocampus in postmortem studies and archival cases independently of the clinical diagnoses and the presence of other neurodegenerative pathologies. Otherwise, the clinical phenotype of C9orf72 mutation carriers, especially in older age groups, may depend on the expansion length, which was not assessed in our series.
The lack of knowledge regarding the actual sequence of events that leads to neurodegeneration in C9orf72 mutation cases does not allow us to determine whether these concomitant pathologies represent another step within the same neurodegenerative process or whether they simply represent an age-related finding. These findings indicate that, besides TDP-43, other pathological protein aggregates may be present in brains with C9orf72 expansion that might also modulate or at least contribute to the clinical phenotype of these diseases.
While the initial clinical manifestation of our series was quite homogenous and consistent with the findings reported so far (24, 26, 27) , age of onset and disease duration was relatively heterogeneous. Almost all patients had behavioral alterations fulfilling criteria of bvFTD, some of them with associated motor neuron disease. In a small fraction of patients, motor neuron involvement was detected only at postmortem investigation and could represent "subclinical" MND. Presentation as motor neuron disease/ALS only was much less frequent. As mentioned before, we identified 4 patients whose clinical diagnosis was Lewy body dementia and indeed 3 of them harbored Lewy body pathology at postmortem in addition to DPR pathology. Recently, the prevalence of the C9orf72 in patients with Lewy body dementia has been studied in a large cohort that included 126 clinical and 1398 neuropathologically confirmed cases. The authors identified no pathogenic repeat expansions and concluded that they were not causally associated with DLB (28) . This contrasts with our results, which may be interpreted as overlapping or concomitant pathologies (FTLD þ LBD). Psychotic symptoms may appear in up to 30% of C9orf72 mutation carriers, which are infrequent in sporadic or other genetic FTLD forms (29, 30) .
In addition, many patients from our series had a positive family history of psychiatric disorders or a nonfurther specified neurodegenerative disease but were not analyzed for the C9orf72 expansion. It is still unclear whether there is any relationship between length of expansion repeats and clinical features among members of the same family (31) (32) (33) .
In summary, this study confirms the high positive predictive value of UPPI for the detection of the C9orf72 expansion, and the utility of its systematic screening by conventional immunohistochemistry in the routine diagnostic setting. While we could not genetically screen the whole archival cases for C9orf72 for eventual cases lacking ubiquitin/p62 inclusions in the cerebellum, immunohistochemistry may allow the identification of clinically nonsuspected or previously not recognized patients with C9orf72 hexanucleotide expansion, with phenotypes other than from the FTD-ALS spectrum, including LBD. While our findings may not translate into other brain banks with different ethnic population and different prevalence of the C9orf72 risk haplotype, the detection of an unexpected genetic cause of the brain donor's pathology has relevant clinical implications for family members and increases the value of well characterized Brain Bank samples.
